Diabetes Mellitus?Diabetic Peripheral Neuropathy?Limb Numbness?Limb Weakness?Pain
Conditions
Interventions
Control group:Administer routine Western medicine treatment to the patient.
Treatment group:In the control group, mecobalamin tablets (Eisai (China) Pharmaceutical Co., Ltd.
National Medicine Standard H20143107) were administered at 0.5 mg three times a day, and beclopulsate sodium tablets (Chengdu Yuandong Biological Pharmaceutical Co., Ltd.
National Medicine Standard H20243696) at 40 µg per dose, three times a day. On this basis, Compound Danshen Dripping Pills (Tasly Pharmaceutical Group Co., Ltd.
National Medicine Standard Z10950111) were added, three times a day, 10 pills per dose.
Sponsors
Huai'an First People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of both Western medicine and Traditional Chinese Medicine (TCM), aged between 50 and 75 years, with a diabetes mellitus duration of 3 to 12 years. 2.Confirmed diagnosis of diabetic peripheral neuropathy for 3 to 8 years. 3.Voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Presence of severe diabetes-related complications, such as severe heart failure, sequelae of stroke, etc. 2. Patients with a known allergy to the drugs used in the study. 3. Presence of peripheral neuropathy attributable to other causes (e.g., alcoholic neuropathy, or neuropathy due to immune disorders, malignancies, etc.). 4. Patients with psychiatric disorders that preclude cooperation with the treatment, as well as those with poor compliance. 5. Diabetic peripheral neuropathy in patients with intact sural nerve function; 6. Type 1 diabetic patient;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensory Nerve Action Potential (SNAP) Amplitude of the Sural Nerve; | — |
Countries
China
Contacts
Public ContactSun Chengmei
Huai'an First People's Hospital
Outcome results
None listed